Inventor · disambiguated record
Nicole Kallewaard-Lelay
Also filed as: KALLEWAARD-LELAY NICOLE
19 granted patents·5 pending applications·56 citations·filing 2014–2025
93Inventor score
Top patents by PatentIndex Score
24 records- 0195US11787853B2Neutralizing anti-influenza b antibodies and uses thereofMEDIMMUNE LLC·Filed 2021·Granted Oct 17, 2023·2 cites·26 claims
- 0295US10442854B2Neutralizing anti-influenza binding molecules and uses thereofMEDIMMUNE LLC·Filed 2016·Granted Oct 15, 2019·13 cites·11 claims
- 0394US11661449B2RSV-specific antibodies and functional parts thereofMEDIMMUNE LLC·Filed 2021·Granted May 30, 2023·2 cites·26 claims
- 0493US12173050B2RSV-specific antibodies and functional parts thereofMEDIMMUNE LTD·Filed 2023·Granted Dec 24, 2024·1 cites·21 claims
- 0593US11186628B2RSV-specific antibodies and functional parts thereofMEDIMMUNE LLC·Filed 2020·Granted Nov 30, 2021·3 cites·11 claims
- 0693US11174304B2Neutralizing anti-influenza B antibodies and uses thereofMEDIMMUNE LLC·Filed 2019·Granted Nov 16, 2021·5 cites·22 claims
- 0792US10689437B2RSV-specific antibodies and functional parts thereofMEDIMMUNE LLC·Filed 2018·Granted Jun 23, 2020·6 cites·16 claims
- 0892US10519221B2Neutralizing anti-influenza B antibodies and uses thereofMEDIMMUNE LLC·Filed 2019·Granted Dec 31, 2019·8 cites·21 claims
- 0989US10882897B2Neutralizing anti-influenza binding molecules and uses thereofMEDIMMUNE LLC·Filed 2019·Granted Jan 5, 2021·3 cites·14 claims
- 1088US2025179153A1Rsv-specific antibodies and functional parts thereofMEDIMMUNE LTD·Filed 2024·Application pending·0 cites
- 1187US12325740B2Neutralizing anti-influenza B antibodies and uses thereofMEDIMMUNE LLC·Filed 2023·Granted Jun 10, 2025·0 cites·16 claims
- 1287US10494419B2Neutralizing anti-influenza A antibodies and uses thereofMEDIMMUNE LLC·Filed 2014·Granted Dec 3, 2019·9 cites·15 claims
- 1386US12492240B2Neutralizing anti-influenza A antibodies and uses thereofMEDIMMUNE LLC·Filed 2024·Granted Dec 9, 2025·0 cites·16 claims
- 1486US10294292B2Neutralizing anti-influenza B antibodies and uses thereofMEDIMMUNE LLC·Filed 2015·Granted May 21, 2019·4 cites·17 claims
- 1584US2025263470A1Neutralizing anti-influenza b antibodies and uses thereofMEDIMMUNE LLC·Filed 2025·Application pending·0 cites
- 1682US11926657B2Neutralizing anti-influenza binding molecules and uses thereofMEDIMMUNE LLC·Filed 2022·Granted Mar 12, 2024·0 cites·13 claims
- 1778US12357692B2Method of treating influenza AMEDIMMUNE LLC·Filed 2022·Granted Jul 15, 2025·0 cites·13 claims
- 1878US2025302952A1Method of treating influenza aMEDIMMUNE LLC·Filed 2025·Application pending·0 cites
- 1976US11932682B2Neutralizing anti-influenza A antibodies and uses thereofMEDIMMUNE LLC·Filed 2021·Granted Mar 19, 2024·0 cites·20 claims
- 2071US11524993B2Neutralizing anti-influenza binding molecules and uses thereofMEDIMMUNE LLC·Filed 2020·Granted Dec 13, 2022·0 cites·14 claims
- 2171US11186627B2Neutralizing anti-influenza A antibodies and uses thereofMEDIMMUNE LLC·Filed 2019·Granted Nov 30, 2021·0 cites·20 claims
- 2266US11547756B2Method of treating influenza AMEDIMMUNE LLC·Filed 2020·Granted Jan 10, 2023·0 cites·11 claims
- 2355US2019015509A1Method of treating influenza aMEDIMMUNE LLC·Filed 2017·Application pending·0 cites
- 2453US2016340414A1Rsv-specific antibodies and functional parts thereofMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →